Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435123 · ClinicalTrials.gov registry record · NA
ProStat Supplementation in Dialysis Patients
A NA study, sponsored by Fresenius Medical Care North America.
- Terminated
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00435123 is a NA study that was terminated before completion, run by Fresenius Medical Care North America. The registered enrollment target is 16 participants.
The verdict
NCT00435123, a NA study, was terminated before completion, sponsored by Fresenius Medical Care North America.
- TERMINATED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a long-term, randomized, placebo-controlled, double blind clinical study of a nutritional supplement, ProStat 64, in chronic hemodialysis patients with poor nutrition. Subjects receive either ProStat 64 or Placebo for three months. At the end of this period, all subjects will receive ProStat-64 for a further 3 months at which time the study is ended. Parameters of nutritional status (lean body mass and serum protein) will be collected at baseline, 3 months and 6 months.
Interventions
- DIETARY_SUPPLEMENT Placebo supplement
- DIETARY_SUPPLEMENT Nutritional Supplement ProStat 64 twice a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435123
The ClinicalTrials.gov registry entry for NCT00435123 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo supplement is the first listed.
NCT00435123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435123 about?
NCT00435123 is a clinical study titled "ProStat Supplementation in Dialysis Patients". This is a long-term, randomized, placebo-controlled, double blind clinical study of a nutritional supplement, ProStat 64, in chronic hemodialysis patients with poor nutrition. Subjects receive either ProStat 64 or Placebo for three months. At the end of this period, all subjects will receive ProStat...
What is the current status of trial NCT00435123?
This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2007-07. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00435123?
The interventions under investigation include: Placebo supplement (DIETARY_SUPPLEMENT), Nutritional Supplement ProStat 64 twice a day (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00435123?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.